Menu Search
Equities

Orchid Pharma Ltd

ORCHPHARMA:NSI

Orchid Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,400.50
  • Today's Change29.60 / 2.16%
  • Shares traded79.22k
  • 1 Year change+168.63%
  • Beta3.4160
Data delayed at least 15 minutes, as of Sep 20 2024 10:36 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Orchid Pharma Ltd grew revenues 23.05% from 6.66bn to 8.19bn while net income improved 98.99% from 463.18m to 921.67m.
Gross margin40.67%
Net profit margin12.78%
Operating margin9.88%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, cash reserves at Orchid Pharma Ltd fell by 189.96m. Cash Flow from Financing totalled 1.67bn or 20.39% of revenues. In addition the company generated 1.26bn in cash from operations while cash used for investing totalled 3.12bn.
Cash flow per share30.05
Price/Cash flow per share47.13
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Orchid Pharma Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.